Omnicell (OMCL) Set to Announce Earnings on Thursday

Share on StockTwits

Omnicell (NASDAQ:OMCL) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, October 25th. Analysts expect the company to announce earnings of $0.40 per share for the quarter. Omnicell has set its Q3 guidance at $0.52-0.57 EPS and its FY18 guidance at $1.90-2.05 EPS.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 26th. The company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.39 by $0.07. Omnicell had a net margin of 5.27% and a return on equity of 5.88%. The business had revenue of $188.70 million during the quarter, compared to analysts’ expectations of $188.80 million. During the same quarter last year, the company earned $0.31 earnings per share. The firm’s revenue was up 4.3% on a year-over-year basis.

NASDAQ OMCL opened at $63.49 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.78 and a quick ratio of 1.27. Omnicell has a twelve month low of $39.75 and a twelve month high of $73.00. The stock has a market capitalization of $2.48 billion, a P/E ratio of 352.72, a P/E/G ratio of 3.12 and a beta of 0.98.

In related news, EVP Dan S. Johnston sold 6,250 shares of the stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $63.47, for a total value of $396,687.50. Following the completion of the sale, the executive vice president now owns 35,996 shares in the company, valued at $2,284,666.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director James T. Judson sold 5,000 shares of the stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $58.76, for a total transaction of $293,800.00. Following the completion of the transaction, the director now directly owns 39,952 shares of the company’s stock, valued at approximately $2,347,579.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,478 shares of company stock valued at $2,812,339. 3.71% of the stock is owned by corporate insiders.

Several research firms recently weighed in on OMCL. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 28th. Craig Hallum increased their target price on shares of Omnicell from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, September 17th. Benchmark increased their target price on shares of Omnicell from $66.00 to $79.00 and gave the company a “buy” rating in a research note on Friday, October 5th. Zacks Investment Research upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Finally, MED reiterated an “in-line” rating and issued a $71.00 target price (up previously from $59.00) on shares of Omnicell in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $67.17.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Read More: Growth Stocks

Earnings History for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply